On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc ...

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Oligonucleotide therapies are among the most promising biological therapeutics. They target disease at a different stage of ...

For decades, lab-made antibodies have been used to support patients fighting specific diseases. These treatments have become ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

Mitochondrial DNA (mtDNA) is actively removed during spermatogenesis in a conserved process that enforces the uniparental ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

OBI-992 is an antibody–drug conjugate (ADC) derived from a novel TROP2-targeted antibody linked to the topoisomerase 1 (TOP1) inhibitor exatecan via an enzyme-cleavable hydrophilic linker, with a drug ...

The purified rabbit pAb were diluted 1:2000 as the primary antibody, and TRITC–conjugated Goat Anti-Rabbit IgG (H + L) (Proteintech, Wuhan, China) was diluted 1:1000 as the secondary antibody for ...